Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. UK/
    2. How we work/
    3. Optimising Disease Reassessment in Inflammatory Bowel Disease Services
    JJ_Photo_Danvers_0430.jpeg

    Optimising Disease Reassessment in Inflammatory Bowel Disease Services

    This collaborative working project between Maidstone and Tunbridge Wells NHS Trust and Johnson & Johnson Innovative Medicine UK focuses on optimising disease reassessment in inflammatory bowel disease (IBD) services. The aim is to better understand current reassessment practice across UK IBD services, identify variation in care pathways and support the co-development of practical, service-led recommendations to improve pathway consistency.
    Background

    National expectations for IBD care highlight the importance of timely disease reassessment, objective monitoring and treat-to-target care. Relevant guidance and standards, including GIRFT recommendations, IBD Standards, NICE guidance and STRIDE-II principles, provide a foundation for services to provide consistent, proactive care for people living with IBD.1-5

    This project provides an opportunity for NHS partners and Johnson & Johnson Innovative Medicine UK to work collaboratively to identify where reassessment pathways can be optimised, share learning across services and co-develop practical, service-led recommendations that support quality improvement and pathway consistency.

    Partnership and Solution
    • Service mapping and variation analysis: NHS partners and Johnson & Johnson Innovative Medicine UK will work together to map current reassessment pathways and review aggregated, non-identifiable service-level information across participating NHS IBD services.
    • Collaborative interpretation of findings: Findings will be compared with relevant national guidance and standards where appropriate, alongside real-world clinical and operational experience from participating services.
    • Co-development of recommendations: A collaborative workshop will discuss findings, explore drivers of variation and identify practical, service-led recommendations to optimise reassessment pathways.
    • Final report and public disclosure: A jointly agreed final report will summarise findings, workshop outputs and recommendations. Project information will be made publicly available in line with ABPI Collaborative Working transparency requirements.
    Benefits

    For patients:

    • Potential for more consistent reassessment pathways across participating IBD services.
    • Service-led recommendations focused on pathway optimisation and patient-centred care.
    • Shared learning to support high-quality, consistent IBD service delivery.

    For participating NHS IBD services:

    • Improved understanding of current reassessment practice and variation across services.
    • Support for benchmarking against relevant national standards and guidance where appropriate.
    • Practical recommendations to inform quality improvement and pathway consistency.

    For Johnson & Johnson Innovative Medicine UK:

    • Opportunity to support a non-promotional collaborative working project focused on service improvement and shared healthcare challenges.
    • Partnership with NHS clinical experts to support optimised pathways that enable clearer therapeutic decision-making in IBD care.

      Download this case study

      Optimising Disease Reassessment in IBD Services: Collaborative Working Project Executive Summary

      Download (84 KB)
      jj-photo-lab-tech-inspecting-substance-in-bottle-im-1star.jpg

      Partner with us

      We are proud to have partnered with the NHS since its inception and are committed to working collaboratively to develop solutions that make a meaningful difference. If you are interested in accelerating innovation or transforming the patient experience in partnership with J&J then please get in touch.
      Interested? Contact our partnerships team

      Explore more collaborative working projects

      1 Getting It Right First Time (GIRFT) (2025) Inflammatory Bowel Disease (IBD) Handbook. London: NHS England. Available at: https://gettingitrightfirsttime.co.uk/wp-content/uploads/2025/11/Inflammatory-Bowel-Disease-IBD-Handbook-FINAL-November-2025.pdf (Accessed: 3 March 2026).

      2 National Institute for Health and Care Excellence (NICE) (2019) Crohn’s disease: management (NICE guideline NG129). London: NICE. Available at: https://www.nice.org.uk/guidance/ng129 (Accessed: 19 March 2026).

      3 National Institute for Health and Care Excellence (NICE) (2019) Ulcerative colitis: management (NICE guideline NG130). London: NICE. Available at: https://www.nice.org.uk/guidance/ng130 (Accessed: 19 March 2026).

      4 IBD UK (n.d.) IBD Standards: Core statements. Available at: https://s3.eu-west-2.amazonaws.com/sr-crohns-craft/documents/IBD-Standards-Core-Statements.pdf (Accessed: 3 March 2026).

      5 Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A.M., Bettenworth, D., Sandborn, W.J., Sands, B.E., Reinisch, W., Schölmerich, J., Bemelman, W., Danese, S., Mary, J.Y., Rubin, D., Colombel, J.F., Peyrin-Biroulet, L., Dotan, I., Abreu, M.T. and Dignass, A. (2021). STRIDE‑II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat‑to‑target strategies in IBD. Gastroenterology, 160(5), pp.1570–1583. doi:10.1053/j.gastro.2020.12.031. Available at: https://pubmed.ncbi.nlm.nih.gov/33359090/ (Accessed: 8 April 2026).1. Getting It Right First Time (GIRFT) (2025) Inflammatory Bowel Disease (IBD) Handbook. London: NHS England. Available at: https://gettingitrightfirsttime.co.uk/wp-content/uploads/2025/11/Inflammatory-Bowel-Disease-IBD-Handbook-FINAL-November-2025.pdf (Accessed: 3 March 2026).

      CP-594073 | August 2026